Cerenome Completes Enrollment in Phase 2 ReSPECT-GBM Trial of REYOBIQ™ in Recurrent Glioblastoma
Cerenome completes enrollment in Phase 2 REYOBIQ trial for recurrent glioblastoma; topline data expected in mid-2027.
Cerenome completes enrollment in Phase 2 REYOBIQ trial for recurrent glioblastoma; topline data expected in mid-2027.